Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882908 · ClinicalTrials.gov registry record · Phase 2
A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment
A Phase 2 study, sponsored by Tibotec Pharmaceuticals, Ireland.
- Completed
- Registry status
- Phase 2
- Development phase
- 386
- Enrollment target
NCT00882908 is a Phase 2 study that has completed, run by Tibotec Pharmaceuticals, Ireland. The registered enrollment target is 386 participants.
The verdict
NCT00882908, a Phase 2 study, has completed, sponsored by Tibotec Pharmaceuticals, Ireland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 386 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of 4 different regimens of TMC435 in combination with peginterferon alfa-2a (PegIFNα-2a) and ribavirin (RBV), defined as the proportion of patients with sustained virologic response at Week 72 (patients with undetectable plasma HCV RNA \[less than 25 IU per mL undetectable\] at the end of treatment and at Week 72), compared to the control group receiving PegIFN and RBV in combination with TMC435-matched placebo.
Interventions
- DRUG Placebo
- DRUG TMC435
- DRUG Ribavirin (R)
- DRUG PegIFNα-2a (P)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00882908
The ClinicalTrials.gov registry entry for NCT00882908 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 386 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tibotec Pharmaceuticals, Ireland, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00882908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00882908 about?
NCT00882908 is a clinical study titled "A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment". The purpose of this study is to evaluate the efficacy of 4 different regimens of TMC435 in combination with peginterferon alfa-2a (PegIFNα-2a) and ribavirin (RBV), defined as the proportion of patients with sustained virologic response at Week 72 (patients with undetectable plasma HCV RNA \[less tha...
What is the current status of trial NCT00882908?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 386 participants. The study started on 2009-06. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00882908?
The interventions under investigation include: Placebo (DRUG), TMC435 (DRUG), Ribavirin (R) (DRUG), PegIFNα-2a (P) (DRUG).
Who is sponsoring clinical trial NCT00882908?
This trial is sponsored by Tibotec Pharmaceuticals, Ireland, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.